Rhumbline Advisers lessened its stake in shares of PetMed Express, Inc. (NASDAQ:PETS) by 30.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 55,075 shares of the company’s stock after selling 24,380 shares during the quarter. Rhumbline Advisers owned about 0.27% of PetMed Express worth $1,826,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Pinebridge Investments L.P. grew its holdings in PetMed Express by 1.0% during the 2nd quarter. Pinebridge Investments L.P. now owns 2,704 shares of the company’s stock valued at $110,000 after buying an additional 27 shares during the last quarter. Acrospire Investment Management LLC acquired a new stake in PetMed Express during the 2nd quarter valued at $110,000. Sei Investments Co. lifted its stake in shares of PetMed Express by 50,142.9% during the 3rd quarter. Sei Investments Co. now owns 3,517 shares of the company’s stock worth $117,000 after purchasing an additional 3,510 shares during the period. Fred Alger Management Inc. purchased a new position in shares of PetMed Express during the 2nd quarter worth $162,000. Finally, Bayesian Capital Management LP purchased a new position in shares of PetMed Express during the 2nd quarter worth $203,000. Hedge funds and other institutional investors own 99.89% of the company’s stock.
PetMed Express, Inc. (NASDAQ:PETS) opened at $43.51 on Wednesday. PetMed Express, Inc. has a 52 week low of $19.21 and a 52 week high of $50.90. The firm has a market capitalization of $879.60, a price-to-earnings ratio of 28.65, a price-to-earnings-growth ratio of 2.56 and a beta of 1.13.
PetMed Express (NASDAQ:PETS) last issued its quarterly earnings results on Monday, October 23rd. The company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.30 by $0.13. PetMed Express had a return on equity of 31.46% and a net margin of 11.58%. The company had revenue of $66.70 million for the quarter, compared to analyst estimates of $63.41 million. During the same quarter in the prior year, the company posted $0.24 EPS. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. analysts anticipate that PetMed Express, Inc. will post 1.67 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Friday, November 17th. Investors of record on Monday, November 6th were given a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 1.84%. The ex-dividend date of this dividend was Friday, November 3rd. PetMed Express’s dividend payout ratio (DPR) is currently 53.69%.
A number of brokerages have weighed in on PETS. BidaskClub raised PetMed Express from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Credit Suisse Group reissued an “underperform” rating and set a $19.00 price target on shares of PetMed Express in a research note on Monday, October 2nd. Zacks Investment Research lowered PetMed Express from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 25th. ValuEngine lowered PetMed Express from a “buy” rating to a “hold” rating in a research note on Monday, October 2nd. Finally, Noble Financial reissued a “hold” rating on shares of PetMed Express in a research note on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. PetMed Express currently has a consensus rating of “Hold” and a consensus target price of $42.00.
In related news, Director Ronald J. Korn sold 1,000 shares of the stock in a transaction on Friday, October 27th. The stock was sold at an average price of $35.57, for a total value of $35,570.00. Following the transaction, the director now directly owns 73,833 shares of the company’s stock, valued at approximately $2,626,239.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 4.00% of the company’s stock.
PetMed Express Company Profile
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Want to see what other hedge funds are holding PETS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PetMed Express, Inc. (NASDAQ:PETS).
Receive News & Ratings for PetMed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express and related companies with MarketBeat.com's FREE daily email newsletter.